According to reports from The Economic Times, Laurus Labs has generated investor wealth of more than ₹40,000 crore in nearly a year, emerging as a multibagger with gains of 120% from its 52-week low. The company's market capitalisation climbed to ₹71,763 crore on the NSE from ₹31,555 crore on May 22, 2025 - the day the stock touched its one-year low of ₹584.50. The Hyderabad-based pharmaceuticals and biotechnology company hit a fresh 52-week high of ₹1,333.50 on Monday, extending its super run on the D-Street. As reported by The Economic Times, its shares are trading above their 50-day and 200-day simple moving averages of ₹1,096 and ₹993 respectively.
According to The Economic Times, the net profit for FY26 stood at ₹889 crore, which increased 148% from ₹358 crore in FY25. Revenues in FY26 stood at ₹6,813 crore, which increased 23% driven by continued strong growth across both CDMO and Affordable Medicine (Generics) divisions. As reported by The Economic Times, the company's profitability has started improving and its operations appear more stable, gradually cementing investor confidence. The brokerage HDFC Securities called the Q4 performance "strong" with Earnings Before, Interest, Taxes, Depreciation and Amortisation (EBITDA) rising 25% YoY and margins expanding 452 basis points to 29%, driven largely by robust growth in the CDMO business and higher gross margins.
According to The Economic Times, institutional participation has risen with mutual funds increasing their holdings for the past four quarters. It stood at 11.2% at the end of March 2026 quarter from 6.9% in March 2025, up 430 basis points. Market expert Anuj Gupta said technical charts are looking positive and investors can expect a further rise in the prices, with strong support at ₹1,150 and resistance at ₹1,400. However, as reported by The Economic Times, HDFC Securities recommended a 'Reduce' rating with a target price of ₹1,130, which the stock has breached decisively. At a trailing-twelve-month P/E of 80, the stock is trading at a premium over its peers like Lupin (17.88), Zydus Lifesciences (19.88), Aurobindo Pharma (24.67) and Biocon (72.80).
According to The Economic Times, considered as defensives, pharma stocks have lived-up to their reputation with the Nifty Pharma index up 15% over the past one year when the headline Nifty index has slipped 6% due to tariff related fears, expensive valuation, foreign outflows and war. Laurus' nearest rival is Glen Pharmaceuticals which is up 62% in the same period. Shares of Gland Pharma, Torrent Pharmaceuticals, JB Chemicals, Biocon, Aurobindo Pharma, Ajanta Pharma, IPCA Laboratories and Wockhardt have been other market outperformers with returns between 18% and 47%. As reported by The Economic Times, the sector's defensive characteristics have helped it weather market volatility effectively.
